Semaglutide: Evidence, Mechanism & Approved Uses

Semaglutide is a 31-amino-acid peptide with approximately 94% sequence homology to human GLP-1. Three deliberate structural modifications separate it from the native hormone. First, a substitution at position 8 prevents cleavage by the enzyme DPP-IV, which normally degrades endogenous GLP-1 within minutes of secretion. Second, a lysine-to-arginine substitution at position 34 removes a secondary DPP-IV recognition site. Third, and most consequential, a C-18 fatty diacid chain is attached via a short linker to lysine-26. This lipid modification drives reversible albumin binding in the bloodstream, dramatically reducing renal clearance and extending the plasma half-life from native GLP-1's approximately two minutes to roughly seven days — the structural basis for its extended pharmacokinetic profile.

Three FDA-approved formulations exist under different brand names. Ozempic is the injectable formulation approved for type 2 diabetes and, based on the SUSTAIN-6 cardiovascular outcomes trial, for reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Wegovy is a higher-exposure injectable formulation approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and additionally — based on the SELECT trial — for cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight without diabetes. Rybelsus is an oral tablet formulation approved for type 2 diabetes; it uses a sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] (SNAC) absorption enhancer to achieve meaningful oral bioavailability — the first oral GLP-1 receptor agonist to reach the market.

Semaglutide's effects flow from agonism at the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed widely across the body. When semaglutide binds, it activates adenylyl cyclase, raising intracellular cyclic AMP (cAMP). Downstream, protein kinase A (PKA) and exchange proteins activated by cAMP (Epac2) coordinate tissue-specific responses.

**Pancreas.** In beta cells, elevated cAMP promotes translocation of insulin secretory granules to the plasma membrane and amplifies insulin release — but only when blood glucose is elevated. This glucose-dependent mechanism is the reason semaglutide carries low intrinsic hypoglycemia risk compared to agents that force insulin secretion regardless of glucose levels. GLP-1R agonism also suppresses glucagon secretion from alpha cells, reducing hepatic glucose output. Animal studies show reduced beta-cell apoptosis and increased proliferation, suggesting a potential disease-modifying role in preserving beta-cell mass, though this translation to humans over multi-year treatment remains under investigation (evidence level: preliminary, mechanistic/animal data).

**Brain and appetite.** GLP-1R is expressed in hypothalamic nuclei (arcuate, paraventricular), the nucleus of the solitary tract (NTS), and the area postrema. Semaglutide activates pro-opiomelanocortin (POMC) neurons and inhibits neuropeptide Y (NPY)/AgRP neurons in the arcuate nucleus, shifting the hypothalamic energy balance set point toward satiety. Activation in the NTS relays meal-induced fullness signals via vagal afferents. Together, these pathways reduce spontaneous caloric intake substantially — a magnitude of effect that, in some trials, approaches the lower end of bariatric-surgery weight-loss ranges (cross-trial comparisons, not head-to-head data), demonstrated across multiple large Phase 3 trials.

**Gut.** Slowed gastric emptying via enteric and vagal GLP-1R signaling extends the window over which nutrients reach the small intestine, reducing postprandial glucose peaks and contributing to earlier satiety.

**Cardiovascular system.** GLP-1R in cardiac muscle, vascular endothelium, and macrophages mediates anti-inflammatory effects, reduced foam-cell formation in atherosclerotic plaques, improved endothelial function, and modest reductions in resting heart rate and systolic blood pressure. These peripheral mechanisms underpin the cardiovascular outcomes benefit demonstrated in large trials.

**Type 2 Diabetes (Ozempic, Rybelsus) — evidence level: strong, multiple large RCTs.** The SUSTAIN program comprised eight Phase 3 randomized controlled trials evaluating the injectable formulation in type 2 diabetes. SUSTAIN-6, the landmark cardiovascular outcomes trial, enrolled adults with T2D at high cardiovascular risk and demonstrated a 26% reduction in major adverse cardiovascular events (MACE: composite of cardiovascular death, non-fatal MI, non-fatal stroke) versus placebo. A particularly notable finding was a significant reduction in stroke events, distinguishing semaglutide from other agents in the class. HbA1c reductions in the SUSTAIN trials were substantial and consistent across baseline HbA1c levels and background therapies.

The PIONEER program (10 Phase 3 trials) established the oral formulation (Rybelsus) for T2D, including active-comparator trials against other glucose-lowering agents. PIONEER 6 provided cardiovascular outcomes data showing non-inferiority on MACE for the oral formulation at the studied exposure level.

**Chronic Weight Management (Wegovy) — evidence level: strong, flagship STEP program.** The STEP (Semaglutide Treatment Effect in People with Obesity) program is the evidence anchor for Wegovy. STEP 1, published in the New England Journal of Medicine in 2021 (Wilding et al.; n=1,961 adults without diabetes), is the pivotal trial: at the higher trial-arm exposure over 68 weeks, mean body weight reduction was 14.9% versus 2.4% with placebo. Approximately one in three participants lost 20% or more of body weight. STEP 2 (n=1,210, participants with T2D comorbidity) showed 9.6% weight loss, establishing that the diabetes population benefits but at a smaller magnitude. STEP 3 (n=611, behavioral counseling co-intervention) achieved 16.0%, showing synergy with lifestyle intervention. STEP 4 (continuation versus withdrawal at 20 weeks) demonstrated rapid weight regain upon discontinuation, with a net difference of approximately 7% between the groups at 48 weeks after withdrawal — a finding with major implications for treatment duration decisions. STEP 5 (104-week extension data) confirmed 15.2% weight loss with sustained therapy, establishing that benefits persist with continued treatment.

**Cardiovascular Risk Reduction in Non-Diabetic Obesity (Wegovy) — evidence level: strong, SELECT trial.** The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023; n=17,604) enrolled adults with pre-existing cardiovascular disease and overweight or obesity but without diabetes. At the higher trial-arm exposure over a median 33.6 months, Wegovy reduced the primary composite endpoint (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% versus placebo. This was the first GLP-1 receptor agonist trial to demonstrate MACE reduction in a non-diabetic population, a landmark finding that shifted the regulatory and prescribing landscape and supported the cardiovascular indication label expansion.

Several active research areas are generating strong scientific interest but have NOT received FDA approval. These are presented here as context for the published literature, not as indications or endorsements.

**Non-alcoholic steatohepatitis (MASH/NASH) — evidence level: moderate-to-strong for histological endpoints, Phase 3 ESSENCE.** The ESSENCE Phase 3 trial evaluated semaglutide in biopsy-confirmed MASH and its results are now published, showing significant histological improvement on the primary endpoint. This represents a meaningful step-up in the evidence tier from the earlier Phase 2 data. Semaglutide is NOT FDA-approved for MASH; this remains an investigational use pending any regulatory submission and review.

**Alzheimer's disease and neurodegeneration — evidence level: preliminary, observational + early Phase 2.** Observational analyses have found associations between GLP-1 receptor agonist use and reduced dementia diagnoses and biomarker changes, but these studies cannot establish causation. GLP-1R is expressed in brain regions involved in neuroinflammation and amyloid clearance pathways, providing a plausible mechanism. Randomized trials are underway but have not reported primary outcomes. NOT approved; causality unestablished.

**Substance use disorders — evidence level: preliminary, small trials.** GLP-1R is expressed in the mesolimbic reward system, and several small randomized trials and cohort studies have reported reduced alcohol craving and consumption. Phase 2 trials in alcohol use disorder and opioid use disorder are ongoing. Insufficient evidence for any clinical recommendation at this time.

**Peripheral artery disease (PAD) — evidence level: preliminary, post-hoc analyses.** Post-hoc analyses from SELECT and SUSTAIN-6 suggest possible reductions in peripheral vascular events, but PAD is not an approved indication and no dedicated PAD trial has reported.

**Prediabetes and prevention — evidence level: moderate, not yet an approved indication.** Trial data show semaglutide significantly reduces progression from prediabetes to type 2 diabetes, but this is not currently an approved indication in the US.

**Gastrointestinal effects — evidence level: strong, consistent across trials.** Nausea is the most commonly reported adverse effect, occurring in approximately 39% of participants at the higher trial-arm exposures in STEP 1, compared to roughly 15% in placebo groups. Vomiting, diarrhea, constipation, and abdominal pain are also more frequent than placebo. GI events are most common in early treatment and typically attenuate over weeks as the body adapts. Severe GI adverse events leading to discontinuation occurred in a minority of participants across trials; rates were generally higher than comparator arms but manageable with standard clinical protocols.

**Hypoglycemia — evidence level: strong.** Semaglutide's glucose-dependent insulin secretion mechanism means that severe hypoglycemia is rare in monotherapy. Risk increases substantially when combined with insulin or sulfonylureas. The SUSTAIN and STEP trials confirmed low rates of severe hypoglycemia in non-insulin-using participants.

**Heart rate — evidence level: strong.** A modest elevation in resting heart rate (approximately 2-4 beats per minute) has been consistently observed across trials. The clinical significance in most patients is considered low but warrants consideration in those with pre-existing cardiac arrhythmias.

**Pancreatitis — evidence level: moderate, signal detected but low absolute risk.** The prescribing labels include a warning about acute pancreatitis. The incidence in clinical trials was low, but semaglutide (and the GLP-1 class broadly) should be used cautiously in patients with a history of pancreatitis. The causal relationship is not definitively established, but the label-level warning reflects the regulatory standard for a plausible mechanistic concern.

**Thyroid C-cell tumors — evidence level: preclinical, class concern.** GLP-1R agonists cause dose- and duration-dependent thyroid C-cell tumors in rodents via a GLP-1R-mediated mechanism. This has not been observed in human trials to date, but semaglutide carries a boxed warning against use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). The FDA requires this warning for the entire GLP-1 RA class based on the rodent data, even absent confirmed human cases.

**Gallbladder disease — evidence level: moderate, several large RCTs.** Cholelithiasis and acute cholecystitis are reported at higher rates with semaglutide than placebo across multiple large trials, likely related to altered bile secretion kinetics from slowed gastric motility and rapid fat mobilization. SELECT reported a statistically significant increase in gallbladder-related events.

**Diabetic retinopathy — evidence level: moderate, SUSTAIN-6 finding.** SUSTAIN-6 reported a statistically significant increase in diabetic retinopathy complications (vitreous hemorrhage, blindness, retinal photocoagulation) versus placebo in T2D patients with pre-existing retinopathy. The proposed mechanism is rapid initial HbA1c reduction triggering early worsening — a phenomenon also seen with insulin intensification. The prescribing label includes monitoring guidance for patients with pre-existing diabetic eye disease.

Semaglutide is FDA-approved as three brand-name products (Ozempic, Wegovy, Rybelsus), all requiring a prescription. Semaglutide is not scheduled under the U.S. Controlled Substances Act and has no DEA schedule.

Following the launch of Wegovy in 2021, demand significantly exceeded supply, leading the FDA to place both Ozempic and Wegovy on its drug shortage list. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, FDA-listed drug shortages create a window during which compounding pharmacies can legally compound copies of the listed drug. This window enabled a large industry of compounding pharmacies to produce and distribute semaglutide-containing preparations. The FDA removed semaglutide from the shortage list in February 2025, and enforcement discretion periods for shortage-based mass compounding subsequently wound down. As of 2026, the FDA is actively enforcing against compounders continuing shortage-based mass production of semaglutide, with enforcement actions including warning letters and injunctions. Patient-specific compounding under existing pharmacy law (503A) remains a narrower, separate matter governed by its own requirements and is not categorically prohibited. Patients who had been using shortage-based compounded semaglutide face prescribing transitions to the branded products.

The compounding episode also raised quality concerns: several FDA adverse event reports associated with compounded semaglutide preparations involved potential dosing errors, with sodium salt formulations (semaglutide sodium) rather than the free-acid form used in approved products. The salt versus free-acid distinction affects potency per unit volume and is not captured in simple milligram labeling on compounded preparations.

Semaglutide is a selective GLP-1 receptor agonist — it acts at one receptor. The next generation of approved and investigational agents add co-agonism at additional receptors:

**Tirzepatide (Mounjaro / Zepbound) — FDA-approved for T2D and obesity.** Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor agonism alongside GLP-1R. Head-to-head trial data (SURMOUNT-5) showed tirzepatide producing meaningfully greater weight loss at the higher trial-arm exposures compared to semaglutide at the higher Wegovy trial-arm, with a statistically significant difference. Tirzepatide is the first FDA-approved dual agonist, representing a step-change in achievable weight loss with a pharmaceutical agent.

**Retatrutide (investigational, not approved) — triple agonist.** Retatrutide adds glucagon receptor agonism to GIP and GLP-1R co-agonism. Phase 2 trial data showed approximately 24% mean weight loss at the highest trial-arm exposures at 48 weeks — substantially higher than either semaglutide or tirzepatide in comparable time frames. Glucagon agonism adds hepatic fat mobilization and energy expenditure components absent from semaglutide. Phase 3 trials are ongoing; no regulatory approval has been granted.

**CagriSema (investigational) — GLP-1R + amylin co-agonism.** CagriSema pairs semaglutide with cagrilintide, a long-acting amylin analog. Phase 3 (REDEFINE program) data have shown weight loss approaching or exceeding tirzepatide-level outcomes, adding amylin's satiety and gastric motility mechanisms to GLP-1R agonism.

**Key differentiators favoring semaglutide.** Semaglutide has one of the longer human safety track records in the class, with a deep cardiovascular outcomes trial dataset spanning both SUSTAIN-6 (T2D population) and SELECT (non-diabetic obesity population). Oral availability (Rybelsus, and higher-exposure oral formulations in late-stage trials) is clinically meaningful for injection-averse patients. The regulatory approval breadth — three separate approved products covering T2D, obesity, and CV risk reduction — is broad across multiple indications and not matched by any newer agent at this time.